NCT00437242终止1 期
A Study to Evaluate the Effect of Repeat Oral Doses of Odiparcil on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 54
- 试验地点
- 2
- 主要终点
- demonstrate lack of effect of repeat dose on QT interval with ECG measured on Days -1, 5 and 6 at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 16, 18, 20 and 24 hours
研究概览
简要总结
This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
demonstrate lack of effect of repeat dose on QT interval with ECG measured on Days -1, 5 and 6 at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 16, 18, 20 and 24 hours
次要结局
- Pharmacokinetics, CMAX, AUC, TMAX, PK samples taken at 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 16, 18, 20 and 24 hours on days 5 and 6
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and PK of Repeated Doses of IRL201104 in Healthy VolunteersHealthy VolunteerNCT04748536Revolo Biotherapeutics18
已完成
不适用
Repeated dosing clinical trial to assess the pharmacokinetic characteristics and safety/tolerability of HL151 formulation in healthy male subjectsKCT0002200Hanlim Pharmaceutical30
撤回
不适用
Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Paediatric Subjects with an Indwelling Central Venous CatheterVein blockage due to clot10014523Venous ThromboembolismNL-OMON36556Bristol-Myers Squibb4
已完成
1 期
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The HeartAtherosclerosisNCT00411073GlaxoSmithKline72
已完成
1 期
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderPsychotic DisordersSchizophreniaBipolar DisorderNCT01094249Johnson & Johnson Pharmaceutical Research & Development, L.L.C.9